Piper Jaffray lowered its price target on Biogen (NASDAQ: BIIB) to $353.00 (from $407.00) while maintaining a Overweight rating.Analyst Chris ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE